How Proposed 2018 OPPS Payment Rules Impact Pharmacy
For 2018, the proposed changes to the OPPS rules have been published in the Federal Register, the comment period has ended, and the final rules will be decided before the year’s end.
Drug Pricing Reform and Cost Containment
With the cost of medications in hospitals, outpatient areas, physician offices and at home surging at an unprecedented rate, emphasis is on drug pricing reform and cost management.
340B Drug Discount Program in 2017
The 340B program is under close scrutiny, with stakeholders reviewing its policies, procedures and discounts, among other issues.
Bundled Payments
The philosophical shift in healthcare payment reform is moving away from fee-for-service to a variety of models, including bundled payments that pay for value.
OPPS 2017 Changes and Opportunities
Recently published proposed changes to the outpatient prospective payment system affect drugs and biologicals. Here are suggestions for how to implement
best practices.
New Part B Drug Payment Models
New proposals, models and rules from the Centers for Medicare and Medicaid Services, the U.S. Food and Drug Administration and the Department of Health and Human Services will affect payments this spring.
Data Collection: A New Regime
An ongoing revolution in healthcare ties data and reimbursement with the demand for analytics that provide insight into a variety of areas.
The Shift to Payment for Value Continues: OPPS 2016 Final Rule
The Centers for Medicare and Medicaid Services issued the final 2016 hospital outpatient prospective payment system and ambulatory payment classification system policy changes and payment rates rule with comment period [CMS-1613-FC] on Oct. 30, 2015.
